HeartSciences (NASDAQ:HSCS), Inc. (NASDAQ: HSCS) is a medical technology company focused on developing and commercializing innovative products for early detection of cardiovascular conditions. Its flagship offering, ECGScan, is a software-based electrocardiogram (ECG) acquisition and analysis platform that integrates artificial intelligence algorithms to enhance cardiac event detection. The company’s solutions are designed for use in primary care settings, emergency departments, urgent care centers and remote monitoring applications, providing clinicians with rapid and reliable diagnostic information to support patient management decisions.
Founded in the early 2000s, HeartSciences has pursued a strategy of combining proprietary digital signal processing with advanced machine learning to improve ECG interpretation. The company holds multiple FDA clearances for its ECGScan platform and related devices, and it continues to invest in research and development to broaden its product pipeline. In addition to on-site ECG acquisition systems, HeartSciences offers cloud-based services that enable healthcare providers to transmit patient ECGs securely for review, storage and analysis, facilitating telemedicine workflows and reducing time to diagnosis.
HeartSciences markets its products and services primarily in the United States, with distribution partnerships in Europe, Asia and Latin America. Its customer base includes hospitals, cardiology practices, urgent care clinics and telehealth providers seeking cost-effective and scalable cardiac screening solutions. The company’s commercial team works closely with clinical partners to validate performance in diverse patient populations and care settings, ensuring that its technologies meet evolving standards of care.
The executive leadership at HeartSciences brings together seasoned professionals from the medical device, diagnostic software and healthcare services industries. The team is led by CEO John R. Chatterton, whose background includes senior roles in cardiovascular diagnostic companies, alongside a board of directors with expertise in regulatory affairs, strategic partnerships and clinical research. Together, they are committed to advancing early detection of heart disease through accessible, data-driven technologies that support better patient outcomes.
